CD274 and Familial prostate cancer: Importantly, treatment with anti-PD-L1 monoclonal antibodies rescued anti-tumor activity of PSCA-CAR T cells in the presence of M2 macrophages, suggesting that PD-L1 is a mediator of M2 macrophage -driven immune suppression in prostate cancer.